Corrigendum: A Nanomule Peptide Carrier Delivers siRNA Across the Intact Blood-Brain Barrier to Attenuate Ischemic Stroke

Eyford, Brett A.; Singh, Chaahat S.B.; Abraham, Thomas; Munro, Lonna; Choi, Kyung Bok; Hill, Tracy; Hildebrandt, Rhonda; Welch, Ian; Vitalis, Timothy Z.; Gabathuler, Reinhard; Gordon, Jacob A.; Adomat, Hans; Guns, Emma S. Tomlinson; Lu, Chieh Ju; Pfeifer, Cheryl G.; Tian, Mei; Jefferies, Wilfred A.

doi:10.3389/fmolb.2021.687587

Cited by 4 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It could be a feasible way to reduce the expression of NOX4 by using NOX4-specific siRNA. It has been demonstrated that a twelve-amino acid peptide (MTfp), derived from melanotransferrin (MTf), could efficiently transport siRNA through the BBB model by forming a novel peptide-oligonucleotide conjugate (POC) [ 106 , 107 ]. MTfp-NOX4 POC further reduced the expression level of NOX4.…”

Section: Therapy For Ischemic Strokementioning

confidence: 99%

Oxidative Injury in Ischemic Stroke: A Focus on NADPH Oxidase 4

Ye²,

Zhu

et al. 2022

Oxidative Medicine and Cellular Longevity

View full text Add to dashboard Cite

Ischemic stroke is a leading cause of disability and mortality worldwide. Thus, it is urgent to explore its pathophysiological mechanisms and find new therapeutic strategies for its successful treatment. The relationship between oxidative stress and ischemic stroke is increasingly appreciated and attracting considerable attention. ROS serves as a source of oxidative stress. It is a byproduct of mitochondrial metabolism but primarily a functional product of NADPH oxidases (NOX) family members. Nicotinamide adenine dinucleotide phosphate oxidase 4 (NOX4) is most closely related to the formation of ROS during ischemic stroke. Its expression is significantly upregulated after cerebral ischemia, making it a promising target for treating ischemic stroke. Several drugs targeting NOX4, such as SCM-198, Iso, G-Rb1, betulinic acid, and electroacupuncture, have shown efficacy as treatments of ischemic stroke. MTfp-NOX4 POC provides a novel insight for the treatment of stroke. Combinations of these therapies also provide new approaches for the therapy of ischemic stroke. In this review, we summarize the subcellular location, expression, and pathophysiological mechanisms of NOX4 in the occurrence and development of ischemic stroke. We also discuss the therapeutic strategies and related regulatory mechanisms for treating ischemic stroke. We further comment on the shortcomings of current NOX4-targeted therapy studies and the direction for improvement.

show abstract

Section: Therapy For Ischemic Strokementioning

confidence: 99%